Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY

Start Learning

Touch Loading image
touchFOCUS
Start Learning
Current treatments and unmet needs in limited-stage small cell lung cancer
CE/CME ACCREDITED
JOURNALS
Start Learning
ESMO Congress 2024 – 13 – 17 September, Barcelona Spain
JOURNALS
Start Learning
Clinical advancements and key presentations: ESGO 2024
touchEXPERT BRIEFING
Start Learning
Front-line consolidation therapy in B-ALL: current challenges and novel strategies
Sponsored content
Larry Holden, CEO GLI
JOURNALS
Start Learning
Overcoming Barriers in Liver Cancer Care: An Interview with Larry R Holden, CEO of Global Liver Institute
touchFOCUS
Start Learning
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
CE/CME ACCREDITED
touchIN CONVERSATION
Start Learning
Knowledge for nurses: ADC updates in breast cancer
CE/CME ACCREDITED
JOURNALS
Start Learning
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023
JOURNALS
Start Learning
Foreword – touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024
touchMEETING HIGHLIGHTS
Start Learning
Quad Pro Quo: Deciphering the role of anti-CD38 quadruplets in newly diagnosed multiple myeloma (NDMM)
Sponsored content

to view Favourites, Keep Notes and Track CME Credits

Favourites
Key data in gastrointestinal cancer: ESOPEC, TRANSMET, COLLISION, ARC-9
View
Targeting Mutant IDH to Treat Low-grade Glioma
View
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
View
Expanding HER2 horizons: Implications for NSCLC and beyond
View
Nivolumab plus Relatlimab alongside chemotherapy demonstrated improved clinical benefit in the RELATIVITY-104 trial
View
Breast cancer highlights: DESTINY-Breast06, postMONARCH, TBCRC 048
View
A Comprehensive Review of the Growing Landscape of Endocrine and Biologic Treatments for Hormone Receptor-positive Breast Cancer
View
Overcoming Barriers in Liver Cancer Care: An Interview with Larry R Holden, CEO of Global Liver Institute
View
Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab
View
Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer
View
In Partnership with...
Useful Links:
About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
Connect With Us:

Other websites from Touch Medical Media:

touchONCOLOGY
touchOPHTHALMOLOGY
touchENDOCRINOLOGY
touchNEUROLOGY
touchCARDIO
touchRESPIRATORY
touchIMMUNOLOGY
touchINFECTIOUS DISEASES
touchHAEMATOLOGY
touchDERMATOLOGY

Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup